DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies

(2015) Shanliang Zhong et al.   CANCER TREATMENT REVIEWS

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

(2015) Masatsugu Hiraki et al.   CHEMISTRY & BIOLOGY

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

(2015) E. M. Alexandrova et al.   NATURE

p53 orchestrates between normal differentiation and cancer

(2015) Noa Rivlin et al.   SEMINARS IN CANCER BIOLOGY

BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

(2015) Xuetian Yue et al.   eLife

Statin use and risk for ovarian cancer: a Danish nationwide case–control study

(2014) L Baandrup et al.   BRITISH JOURNAL OF CANCER

Statins: protectors or pretenders in prostate cancer?

(2014) Hyeongsun Moon et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials

(2013) Xiao-long Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells

(2013) S Masciarelli et al.   ONCOGENE

Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway

(2012) William A. Freed-Pastor et al.   CELL

Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers

(2011) Shouji Shimoyama   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

p53 Research: The Past Thirty Years and the Next Thirty Years

(2010) D. Lane et al.   Cold Spring Harbor Perspectives in Biology

Identification of a consensus motif in substrates bound by a Type I Hsp40

(2009) P. Kota et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT

Chaperone-dependent stabilization and degradation of p53 mutants

(2008) P Muller et al.   ONCOGENE

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

(2008) F. M. Boeckler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA